MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

FibroGen Company Profile (NASDAQ:FGEN)

Consensus Ratings for FibroGen (NASDAQ:FGEN) (?)
Ratings Breakdown: 1 Hold Rating(s), 4 Buy Rating(s)
Consensus Rating:Buy (Score: 2.80)
Consensus Price Target: $33.50 (110.82% upside)

Analysts' Ratings History for FibroGen (NASDAQ:FGEN)
Show:
DateFirmActionRatingPrice TargetActions
5/25/2016Credit SuisseReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/22/2016Goldman SachsLower Price Target$34.00 -> $31.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
12/29/2015Leerink SwannReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
12/4/2015Citigroup Inc.Initiated CoverageBuy$40.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
9/23/2015Lake Street CapitalInitiated CoverageHold$25.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
12/9/2014Stifel NicolausInitiated CoverageBuy$39.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
12/9/2014RBC CapitalInitiated CoverageOutperform$38.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
12/8/2014William BlairInitiated CoverageOutperformView Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 6/29/2014 forward)
Earnings History for FibroGen (NASDAQ:FGEN)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/11/2016        
5/9/2016Q116($0.56)($0.45)$17.74 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/29/2016Q4($0.54)($0.85)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/12/2015Q3($0.61)($0.74)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/13/2015Q215$0.73$0.83$111.75 million$120.55 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/12/2015Q115($0.52)($0.78)$34.00 million$16.30 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/26/2015Q414($0.90)($0.82)$16.49 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)
Earnings Estimates for FibroGen (NASDAQ:FGEN)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20164($0.84)($0.59)($0.70)
Q2 20164$0.15$0.43$0.30
Q3 20163($0.61)($0.41)($0.51)
Q4 20163($0.73)($0.60)($0.67)
Q1 20171($0.72)($0.72)($0.72)
Q2 20171($0.73)($0.73)($0.73)
Q3 20171($0.74)($0.74)($0.74)
Q4 20171($0.80)($0.80)($0.80)
(Data provided by Zacks Investment Research)
Dividend History for FibroGen (NASDAQ:FGEN)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading History for FibroGen (NASDAQ:FGEN)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
6/15/2016Pat CotroneoCFOSell1,796$16.49$29,616.04View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/15/2016Thomas B NeffCEOSell27,000$16.48$444,960.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/10/2016K Peony YuInsiderSell2,344$17.96$42,098.24View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/3/2016Thomas B NeffCEOSell27,000$18.99$512,730.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/20/2016Thomas B NeffCEOSell27,000$17.68$477,360.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/16/2016Pat CotroneoCFOSell6,107$17.60$107,483.20View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/3/2016Thomas B NeffCEOSell27,000$17.78$480,060.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/20/2016Thomas B NeffCEOSell27,000$19.98$539,460.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/19/2016Thomas B NeffCEOSell13,500$20.21$272,835.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/5/2016Thomas B NeffCEOSell27,000$21.11$569,970.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/1/2016Frank H Md ValoneInsiderSell10,750$21.11$226,932.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/22/2016Thomas B NeffCEOSell27,000$18.74$505,980.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/8/2016Thomas B NeffCEOSell27,000$19.62$529,740.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/1/2016Frank H Md ValoneInsiderSell10,750$16.84$181,030.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/23/2016Thomas B NeffCEOSell27,000$19.11$515,970.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/22/2016Thomas B NeffCEOSell13,500$19.81$267,435.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/16/2016Frank H. Md ValoneinsiderSell10,750$18.41$197,907.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/10/2016Thomas B. NeffCEOSell27,000$15.31$413,370.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/29/2016Thomas B. NeffCEOSell27,000$19.41$524,070.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/21/2016Thomas F Kearns JrDirectorSell1,572$22.08$34,709.76View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/14/2016Thomas B. NeffCEOSell27,000$23.69$639,630.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/24/2015Thomas F. Kearns, Jr.DirectorSell7,800$30.88$240,864.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/23/2015Thomas B. NeffCEOSell27,000$30.10$812,700.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/11/2015Thomas B. NeffCEOSell27,000$29.59$798,930.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/10/2015K Peony YuVPSell1,093$28.96$31,653.28View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/8/2015Miguel MaderoDirectorSell40,386$30.49$1,231,369.14View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/30/2015K Peony YuVPSell5,000$30.00$150,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/25/2015Pat CotroneoCFOSell5,000$30.00$150,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/24/2015Thomas B. NeffCEOSell13,500$28.98$391,230.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/24/2015Thomas F. Kearns, Jr.DirectorSell3,900$29.00$113,100.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/23/2015Thomas B. NeffCEOSell13,500$27.99$377,865.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/23/2015Thomas F. Kearns, Jr.DirectorSell3,900$28.02$109,278.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/17/2015K Peony YuVPSell5,000$28.00$140,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/10/2015K Peony YuVPSell5,000$25.62$128,100.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/9/2015K Peony YuVPSell2,500$25.00$62,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/2/2015Frank H. Md ValoneinsiderSell10,000$23.18$231,800.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/30/2015Thomas B. NeffCEOSell27,000$24.06$649,620.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/21/2015Thomas F. Kearns, Jr.DirectorSell7,800$23.83$185,874.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/19/2015Frank H. Md ValoneinsiderSell10,000$23.00$230,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/19/2015K Peony YuVPSell5,000$24.00$120,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/16/2015K Peony YuVPSell5,000$21.46$107,300.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/16/2015Thomas B. NeffCEOSell27,000$21.86$590,220.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/2/2015Thomas B. NeffCEOSell27,000$21.59$582,930.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/1/2015Frank H. Md ValoneinsiderSell10,000$21.38$213,800.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/18/2015Thomas B. NeffCEOSell27,000$29.10$785,700.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/15/2015Pat CotroneoCFOSell1,093$27.95$30,549.35View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/14/2015Rory B. RiggsDirectorSell50,000$27.61$1,380,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/11/2015Miguel MaderoDirectorSell20,600$27.66$569,796.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/10/2015K Peony YuVPSell1,093$27.84$30,429.12View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/10/2015Pat CotroneoCFOSell7,500$27.33$204,975.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/4/2015Thomas B. NeffCEOSell13,500$22.88$308,880.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/3/2015Thomas B. NeffCEOSell13,500$22.92$309,420.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/1/2015Frank H. Md ValoneinsiderSell10,000$23.58$235,800.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/23/2015Thomas B NeffCEOSell27,000$24.71$667,170.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/20/2015Frank H Md ValoneInsiderSell1,000$23.70$23,700.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/20/2015Pat CotroneoCFOSell7,881$23.47$184,967.07View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/9/2015Thomas B NeffCEOSell27,000$22.11$596,970.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/6/2015K Peony YuVPSell5,381$22.69$122,094.89View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/25/2015Thomas B NeffCEOSell27,000$23.57$636,390.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)
Latest Headlines for FibroGen (NASDAQ:FGEN)
DateHeadline
06/25/16 03:49 PMStock Tracing Lower on the Week FibroGen, Inc. (NASDAQ:FGEN) - Engelwood Daily
06/24/16 10:51 AMFibroGen, Inc (NASDAQ:FGEN) Earnings Glance and Target Price Review - Engelwood Daily
06/23/16 03:04 PMFibroGen, Inc (NASDAQ:FGEN) Yearly Sales Target At $1071.09 - Investor Newswire
06/22/16 08:42 AMFibroGen, Inc. (NASDAQ:FGEN) Went Down -1.69%: Infinity Pharmaceuticals, Inc. (NASDAQ:INFI), Tesla Motors Inc ... - KC Register
06/15/16 08:43 AMFibroGen, Inc (NASDAQ:FGEN) Trading Down – Insider Trading Activity
06/10/16 04:30 PMFIBROGEN INC Files SEC form 8-K, Change in Directors or Principal Officers, Submission of Matters to a Vote of Securi -
06/10/16 06:22 AMFibroGen, Inc. (NASDAQ:FGEN) Near to Lift Curtain on June 2016 Earnings - iStreetWire
06/09/16 06:19 AMFibroGen Announces Initiation by Astellas of Phase 3 Clinical Study in Japan of Roxadustat/ASP1517 for the Treatment of Anemia of Chronic Kidney Disease Triggering $10.0 Million Milestone Payment - [at noodls] - SAN FRANCISCO, June 09, 2016 (GLOBE NEWSWIRE) -- FibroGen, Inc. (Nasdaq:FGEN) ('FibroGen'), announced today that it will receive a $10.0 million milestone payment from Astellas Pharma Inc. (Astellas). ...
06/09/16 06:07 AMFIBROGEN INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits -
06/06/16 03:53 PMFIBROGEN INC. (NASDAQ:FGEN) Financial Condition Compared to S&P 500 - CML News
06/06/16 06:08 AMFibroGen to Present at the Goldman Sachs 37th Annual Global Healthcare Conference - [at noodls] - SAN FRANCISCO, June 06, 2016 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN), announced that Chief Executive Officer, Thomas B. Neff, will be presenting at the Goldman Sachs 37th Annual Global Healthcare ...
06/03/16 10:11 PMFibroGen Inc (FGEN) CEO Sells $512730.00 in Stock - Let Me Know About This
06/03/16 07:07 AMFibroGen, Inc. breached its 50 day moving average in a Bullish Manner : FGEN-US : June 3, 2016 -
06/02/16 10:05 PMNews Sentiment For FibroGen, Inc (NASDAQ:FGEN) - Investor Newswire - News Sentiment For FibroGen, Inc (NASDAQ:FGEN)Investor NewswireFor measuring this sentiment, the news is tracked from different channels. But it has to be noted that only the most relevant and buzzing articles are considered to get a rational sentiment score. FibroGen, Inc (NASDAQ:FGEN) has been given a sentiment ...and more »
05/29/16 01:00 PMChairman’s Message during the FPH meeting on May 23, 2016 - [at noodls] - May 29, 2016 Six years ago we decided to express in a few words the vision of First Philippine Holdings Corp., which is to: 'Uplift lives through key industries and infrastructure that advance national ...
05/19/16 06:24 PMETF’s with exposure to FibroGen, Inc. : May 19, 2016 -
05/17/16 01:45 PMFibroGen, Inc. :FGEN-US: Earnings Analysis: Q1, 2016 By the Numbers -
05/10/16 11:09 AMEdited Transcript of FGEN earnings conference call or presentation 9-May-16 8:30pm GMT -
05/09/16 03:46 PMFIBROGEN INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits -
05/09/16 03:18 PMFibroGen Reports Financial Results for the First Quarter of 2016 - [at noodls] - Continued Progress in Roxadustat Phase 3 Studies; Promising Interim Pancreatic Cancer Data -Webcast Conference Call Scheduled for 4:30pm EST Today- SAN FRANCISCO, May 09, 2016 (GLOBE NEWSWIRE) -- FibroGen, ...
05/09/16 06:07 AMQ1 2016 FibroGen Inc Earnings Release - After Market Close -
05/02/16 03:30 PMFibroGen to Report First Quarter 2016 Financial Results on May 9, 2016 - [at noodls] - SAN FRANCISCO, May 02, 2016 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN), a research-based biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics ...
04/29/16 01:13 PMETF’s with exposure to FibroGen, Inc. : April 29, 2016 -
04/28/16 07:14 AMFibroGen, Inc. breached its 50 day moving average in a Bearish Manner : FGEN-US : April 28, 2016 -
04/20/16 10:22 PMPromising Phase 2 Data Show Roxadustat Corrected Anemia in Chronic Kidney Disease Patients Before Intervention with Dialysis - [at noodls] - SAN FRANCISCO, April 20, 2016 (GLOBE NEWSWIRE) -- FibroGen, Inc. (Nasdaq:FGEN) ('FibroGen'), a research-based biopharmaceutical company, today announced that the Clinical Journal of the American Society ...
02/19/16 06:00 AMFibroGen to Report Fourth Quarter and Full Year 2015 Financial Results on February 29, 2016 - [GlobeNewswire] - SAN FRANCISCO, Feb. 19, 2016-- FibroGen, Inc., a research-based biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics to treat serious unmet medical ...
02/16/16 01:27 PMFibrogen Gains On Strong Phase 2 Data - Shares of FibroGen Inc (NASDAQ: FGEN) were trading higher by nearly 3 percent on Tuesday after the company reported that the American Journal of Kidney Disease has published encouraging Phase 2 data. FibroGen noted that the Phase 2 data showed that roxadustat, the company's investigational oral agent for the treatment of anemia in patients with chronic kidney diseases, maintained "emoglobin levels among patients on hemodialysis previously treated with and switched from epoetin alfa ─ regardless of baseline iron repletion status, degree of ...Full story available on Benzinga.com
02/16/16 06:20 AMFibroGen Publishes Encouraging Phase 2 Anemia Data Demonstrating Roxadustat’s Ability to Maintain Hemoglobin Levels in Patients With Chronic Kidney Disease - [GlobeNewswire] - SAN FRANCISCO, Feb. 16, 2016-- FibroGen, Inc., a research-based biopharmaceutical company, today announced that the American Journal of Kidney Disease has published Phase 2 data showing roxadustat, an ...
02/11/16 05:11 AMFIBROGEN INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits -
02/02/16 01:48 PMCompany Shares of FibroGen, Inc (NASDAQ:FGEN) Drops by -3.06% - Market Briefing - Company Shares of FibroGen, Inc (NASDAQ:FGEN) Drops by -3.06%Market BriefingFibroGen, Inc (NASDAQ:FGEN) has lost 3.06% during the past week and dropped 33.44% in the last 4 weeks. The shares are however, negative as compared to the S&P 500 for the past week with a loss of 4.73%. FibroGen, Inc (NASDAQ:FGEN) has ...FibroGen Inc (FGEN) CEO Thomas B. Neff Sells 27000 Shares of StockZolmaxall 2 news articles »
02/02/16 01:48 PMSentiment And Earnings Update For FibroGen, Inc (NASDAQ:FGEN) - Investor Newswire - Sentiment And Earnings Update For FibroGen, Inc (NASDAQ:FGEN)Investor NewswireZacks Research, combined analysts opinion on FibroGen, Inc (NASDAQ:FGEN) and gave an average broker rating of 1.5. The research firm rating mechanism takes into account the research firms' forecasts on a one to five scale. As per the methodology, the ...and more »
01/29/16 01:31 PMFibroGen, Inc (NASDAQ:FGEN) Short Interest Update - Bull Report - FibroGen, Inc (NASDAQ:FGEN) Short Interest UpdateBull ReportFibroGen, Inc (NASDAQ:FGEN), A rise of 123,984 shares or 3.8% was seen in the short interest of FibroGen, Inc. Even as the interest increased from 3,274,199 shares on December 31,2015 to 3,398,183 shares on January 15,2016, the days to cover came in ...What Is the Buzz Surrounding FibroGen, Inc (NASDAQ:FGEN)?Vanguard TribuneSentiment And Earnings Update For FibroGen, Inc (NASDAQ:FGEN)Investor Newswireall 3 news articles »
01/28/16 01:26 PMFibroGen (FGEN) Is Weak On High Volume Today - TheStreet.com - FibroGen (FGEN) Is Weak On High Volume TodayTheStreet.comFIBROGEN INC's earnings per share declined by 5.7% in the most recent quarter compared to the same quarter a year ago. This year, the market expects an improvement in earnings (-$1.07 versus -$1.59). Looking at the price performance of FGEN's shares ...and more »
01/28/16 02:28 AM3:28 am FibroGen reports early Phase 2 data from a clinical study of FG-3019; generally well tolerated -
01/27/16 08:44 PMFibroGen Announces Early Phase 2 Data From a Clinical Study of FG-3019 in Combination With Chemotherapy as Neoadjuvant in Locally Advanced, Unresectable Pancreatic Cancer - [at noodls] - , (GLOBE NEWSWIRE) -- () today announced early results from a Phase 2, randomized, open-label study of FG-3019, an investigational anti-fibrotic antibody, in combination with gemcitabine and nab-paclitaxel ...
01/27/16 12:52 PMCommit To Purchase FibroGen At $12.50, Earn 15% Annualized Using Options - Investors eyeing a purchase of FibroGen Inc (Symbol: FGEN) shares, but cautious about paying the going market price of $19.71/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put ...
01/21/16 05:19 AMCoverage initiated on FibroGen by Credit Suisse -
01/18/16 11:38 AMStock Grabbing Investor's Attention: FibroGen Inc - iStreetWire - Stock Grabbing Investor's Attention: FibroGen InciStreetWireThe shares of FibroGen Inc (NASDAQ:FGEN) had been given positive outlook from Sell-side analysts. Based on the poll results published by the Zacks Research, the stock of the company has been assigned a 1.50 rating. The rating score is on a scale of 1 ...
01/07/16 07:09 AMFibroGen, Inc. breached its 50 day moving average in a Bearish Manner : January 7, 2016 -
01/06/16 04:47 PMFibroGen Enrolls First Patients in Phase 2 Clinical Study of Anti-Fibrotic Drug Candidate FG-3019 for the Treatment of Duchenne Muscular Dystrophy - [GlobeNewswire] - SAN FRANCISCO, Jan. 06, 2016-- FibroGen, Inc. announced today enrollment of the first two patients in an open-label, multicenter Phase 2 clinical trial of the investigational compound FG-3019 in patients ...
01/05/16 07:55 PMGilead suffers setback with biotech drug aimed at killer lung disease -
01/04/16 09:05 AMTop Biotech Stock Favorites to Buy With Up to 100% Upside Potential -
12/18/15 04:01 PMFIBROGEN INC Files SEC form 8-K, Change in Directors or Principal Officers -
12/14/15 06:01 AMAkebia Secures Asian Partner and Funding for Anemia Pill -
12/08/15 12:17 PMFIBROGEN INC Financials -
12/07/15 10:17 AMFibroGen, Inc. Earnings Analysis: Q3, 2015 By the Numbers -
11/25/15 10:39 AMIs Scholastic Corp (SCHL) Going to Burn These Hedge Funds? -
11/18/15 07:00 AMStrength Seen in FibroGen (FGEN): Stock Rises 6.3% -
11/15/15 10:11 PMPRESS STATEMENT: First Gen reports 3Q2015 attributable net income at USD120 million - [at noodls] - November 13, 2015 First Gen Corporation (First Gen) reported net income attributable to equity holders of the parent of USD120 million for the first nine months of 2015. This was a 26%, or a USD43 million, ...
11/13/15 04:15 PMEdited Transcript of FGEN earnings conference call or presentation 12-Nov-15 9:30pm GMT -
About FibroGen

FibroGen logoFibroGen, Inc. is a research-based biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of novel therapeutics to treat serious unmet medical needs. Its lead product candidate is roxadustat (FG-4592). It is also engaged in developing products, such as FG-6874, FG-3019 and FG-5200. FG-4592 is an oral small molecule inhibitor of hypoxia-inducible factor-prolyl hydroxylases (HIF-PHs), which acts by stimulating the body's natural pathway of erythropoiesis or red blood cell production. FG-4592 is in Phase III clinical development for the treatment of anemia in chronic kidney disease (CKD). FG-3019 is a monoclonal antibody, which is in Phase II clinical development for the treatment of idiopathic pulmonary fibrosis (IPF), pancreatic cancer, Duchenne muscular dystrophy (DMD) and liver fibrosis. FG-6874 is in Phase I clinical trials, and FG-5200 is a corneal implant medical device, which is in preclinical studies.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: FGEN
  • CUSIP:
Key Metrics:
  • Previous Close: $15.89
  • 50 Day Moving Average: $17.45
  • 200 Day Moving Average: $20.21
  • P/E Ratio: N/A
  • P/E Growth: 0.00
  • Market Cap: $992.33M
  • Current Quarter EPS Consensus Estimate: $-1.02 EPS
Additional Links:
FibroGen (NASDAQ:FGEN) Chart for Wednesday, June, 29, 2016


            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha